Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris

Paris, France

Share

Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris
Meet MGI Team at the 12th Edition of the Assises de Génétique Humaine et Médicale in Paris

MGI Tech is delighted to announce its participation in the 12th Assises de Génétique Humaine et Médicale, set to unfold from January 9th to 12th, 2024 at the Palais des Congrès in Paris. This prestigious event brings together the brightest minds in the field of human and medical genetics, providing a unique platform to share the latest scientific advances, innovative discoveries, and best practices.

Our team will be present to engage in exciting discussions and exchange innovative ideas during our Lunch Symposium on Thursday, January 11th.

We kindly invite you to mark your calendars and join us at booth number 19, where you can learn more about our latest developments, and ongoing projects, and engage with our experts for exciting discussions. 

For more details regarding the event, please visit assises-genetique.org.

MGI Tech is delighted to announce its participation in the 12th Assises de Génétique Humaine et Médicale, set to unfold from January 9th to 12th, 2024 at the Palais des Congrès in Paris. This prestigious event brings together the brightest minds in the field of human and medical genetics, providing a unique platform to share the latest scientific advances, innovative discoveries, and best practices.

Our team will be present to engage in exciting discussions and exchange innovative ideas during our Lunch Symposium on Thursday, January 11th.

We kindly invite you to mark your calendars and join us at booth number 19, where you can learn more about our latest developments, and ongoing projects, and engage with our experts for exciting discussions. 

For more details regarding the event, please visit assises-genetique.org.

MGI Tech is delighted to announce its participation in the 12th Assises de Génétique Humaine et Médicale, set to unfold from January 9th to 12th, 2024 at the Palais des Congrès in Paris. This prestigious event brings together the brightest minds in the field of human and medical genetics, providing a unique platform to share the latest scientific advances, innovative discoveries, and best practices.

Our team will be present to engage in exciting discussions and exchange innovative ideas during our Lunch Symposium on Thursday, January 11th.

We kindly invite you to mark your calendars and join us at booth number 19, where you can learn more about our latest developments, and ongoing projects, and engage with our experts for exciting discussions. 

For more details regarding the event, please visit assises-genetique.org.

MGI Tech is delighted to announce its participation in the 12th Assises de Génétique Humaine et Médicale, set to unfold from January 9th to 12th, 2024 at the Palais des Congrès in Paris. This prestigious event brings together the brightest minds in the field of human and medical genetics, providing a unique platform to share the latest scientific advances, innovative discoveries, and best practices.

Our team will be present to engage in exciting discussions and exchange innovative ideas during our Lunch Symposium on Thursday, January 11th.

We kindly invite you to mark your calendars and join us at booth number 19, where you can learn more about our latest developments, and ongoing projects, and engage with our experts for exciting discussions. 

For more details regarding the event, please visit assises-genetique.org.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

About MGI

MGI Tech Co., Ltd. (MGI) is at the forefront of global innovation, actively contributing to life science through intelligent innovation. With a presence in over 100 countries and a customer base of 2600+, MGI's cutting-edge technology has been instrumental in the development of 736+ user patents, facilitating the creation of over 150 petabytes of data. The company's extensive portfolio includes sequencing instruments, automation instruments, reagents, and related products that cater to various sectors such as life science research, agriculture, precision medicine, and healthcare.

MGI is dedicated to advancing life science tools for the healthcare of the future. As of December 2021, the company's global presence has expanded to more than 100 countries and regions, serving over 1,300 international clients. With a workforce of over 2,900 professionals worldwide, including 5 centers for research and development and production facilities in Europe, MGI is committed to fostering innovation. Approximately 35% of MGI's employees are engaged in R&D, underscoring the company's focus on pioneering advancements in the field.

The impact of MGI's work is further evidenced by the publication of over 6,800 papers in prestigious scientific journals, showcasing the significant contribution of MGI's technology to the scientific community and beyond.

For more information about MGI and its contributions to life science and healthcare, please visit the MGI website or connect with us on Twitter, LinkedIn, or YouTube.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

MGI-tech stands at the forefront of the biotechnological revolution, having firmly established its dominance in the field of gene sequencing and life science innovation. With the recent accolade of the Globee® for Medical Equipment, awarded to their DNBSEQ-T20×2 gene sequencing platform, MGI's trajectory towards pioneering unprecedented advancements in genetics is clear and commendable.

A Beacon of Innovation: The Globee® Awards The Globee® Awards shine a spotlight on entities that redefine industry standards through ingenuity and ambition. As a platform recognizing the zenith of business excellence, it honors MGI among other titans like Amazon and IBM, underscoring the company’s vision and execution in propelling the genetic industry forward. Garnering this award for the second time in succession, MGI reaffirms its stature as an innovator par excellence.

The DNBSEQ-T20×2: A Technological Marvel February 2023 saw the launch of MGI's DNBSEQ-T20×2, affectionately termed 'T20*', which epitomizes the cutting edge of gene sequencing technology. Engineered for ultra-high-throughput sequencing, the T20* is a beacon of affordability and efficiency, democratizing genome sequencing and catalyzing a new era of medical breakthroughs in health monitoring and disease prevention.

The Economic and Healthcare Revolution A crucial milestone achieved by the T20* is the reduction of genome sequencing costs to under $100, a leap forward in making personalized medicine a universal standard. This seismic shift promises to accelerate our understanding of the human genome, with far-reaching implications for medical research and the broader healthcare industry.

MGI's Visionary Leadership and Future Aspirations Duncan Yu, President of MGI, articulates the company's pride and reinforced commitment to advancing research and improving healthcare outcomes following the Globee® victory. The company’s relentless drive to break barriers in sequencing capacity and cost-efficiency resonates through its continued innovations and strategic partnerships, poised to propel the life science industry towards a future where precision medicine is not just a possibility, but a norm.

Conclusion: MGI's journey is marked by persistent pursuit of excellence and innovation. With its unique DNBSEQ technology and the T20* sequencing platform, MGI is not merely participating in the life science industry; it is actively sculpting its growth and direction. As MGI continues to forge alliances and foster advancements, its impact transcends the company itself, positioning it as a pivotal architect in the evolving narrative of global healthcare and life science.

LIFE SCIENCE INNOVATION

MEDICAL GENETICS

HUMAN GENETICS

PARIS CONFERENCE

NGS

Share this article :

Share

More Events

Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024
Join MGI at Spatial Biology UK 2024

Mar 18, 2024

Join MGI at Spatial Biology UK 2024

Discover Genomic Innovations with MGI at Spatial Biology UK 2024! Join us on March 18th-19th at booth 15 at Novotel London West. Don't miss out!

Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference
Join us at EACR-AACR-IACR Basic and Translational Research Conference

Jan 27, 2024

Join us at EACR-AACR-IACR Basic and Translational Research Conference

Join us at booth 5 during the EACR-AACR-IACR Basic and Translational Research Conference with the MGI Team in Dublin, Ireland from February 27-29.

Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January
Join us at The Festival of Genomics & Biodata in January

Jan 24, 2024

Join us at The Festival of Genomics & Biodata in January

Join us at booth 98 with MGI Tech during The Festival of Genomics & Biodata on January 24th-25th, 2024, at ExCeL in London.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.

Copyright © 2024 MGI tech GmbH, Ltd. All Rights Reserved.